Mine Safety and Health Research Advisory Committee, National Institute for Occupational Safety and Health (MSHRAC, NIOSH), 40622 [2012-16776]

Download as PDF 40622 Federal Register / Vol. 77, No. 132 / Tuesday, July 10, 2012 / Notices 5. Following a structured process (e.g., modified Delphi), provide specific input to support or modify the proposed mappings (about 2.5 hours). 6. Participate in teleconference to discuss areas of disagreement among workgroup members, and to achieve consensus when possible (1.5 hours). 7. Following a structured process (e.g., modified Delphi), provide specific input to support or modify the proposed mappings, incorporating changes accepted in previous steps (about 1.0 hour). 8. Participate in final (optional) teleconference to review final recommendations and discuss contextual issues (1.0 hour). Please note that should additional conference calls be necessary, workgroup members are expected to make every effort to participate. The workgroups will conduct business by telephone, email, or other electronic means as needed. Background The AHRQ Quality Indicators (AHRQ QIs) are a unique set of measures of health care quality that make use of readily available hospital inpatient administrative data. The QIs have been used for various purposes. Some of these include tracking, hospital selfassessment, reporting of hospitalspecific quality or pay for performance. The AHRQ QIs are provider- and arealevel quality indicators and currently consist of four modules: the Prevention Quality Indicators (PQI), the Inpatient Quality Indicators, the Patient Safety Indicators (PSI), and the Pediatric Quality Indicators (PedQIs). AHRQ is committed to converting the QIs from ICD–9–CM to ICD–10–CM/PCS in an accurate and transparent manner, taking advantage of the additional specificity of ICD–10–CM/PCS to improve the validity and usefulness of the QIs, from October 2014 onward. Dated: July, 2, 2012. Carolyn M. Clancy, AHRQ Director. [FR Doc. 2012–16734 Filed 7–9–12; 8:45 am] mstockstill on DSK4VPTVN1PROD with NOTICES BILLING CODE 4160–90–M DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Food and Drug Administration Mine Safety and Health Research Advisory Committee, National Institute for Occupational Safety and Health (MSHRAC, NIOSH) Anti-Infective Drugs Advisory Committee; Notice of Meeting In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting for the aforementioned committee: Times and Dates: 8:30 a.m.–5:15 p.m., August 20, 2012 8:30 a.m.–4:30 p.m., August 21, 2012 Place: Hilton Garden Inn Pittsburgh/ Southpointe, 1000 Corporate Drive, Canonsburg, Pennsylvania 15317. Telephone: (724) 743–5000, Fax: (724) 743–5010. Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people. Purpose: This committee is charged with providing advice to the Secretary, Department of Health and Human Services; the Director, CDC; and the Director, NIOSH, on priorities in mine safety and health research, including grants and contracts for such research, 30 U.S.C. 812(b)(2), Section 102(b)(2). Matters To Be Discussed: The meeting will focus on engineering noise controls, reducing coal dust exposures, reducing injuries through improved illumination, demographics survey of the mining industry, implementation of the National Academy of Science’s recommendations, oxygen supply partnership, safety culture, occupational health and safety management systems, preventing coal dust explosions, and reducing silica exposures. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Jeffery L. Kohler, Ph.D., Designated Federal Officer, MSHRAC, NIOSH, CDC, 626 Cochrans Mill Road, Mailstop P05, Pittsburgh, Pennsylvania 15236, telephone (412) 386–5301, fax (412) 386–5300. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. [FR Doc. 2012–16776 Filed 7–9–12; 8:45 am] BILLING CODE 4163–18–P 16:28 Jul 09, 2012 Jkt 226001 AGENCY: Food and Drug Administration, HHS. Dated: July 2, 2012. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. VerDate Mar<15>2010 [Docket No. FDA–2012–N–0001] PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public. Name of Committee: Anti-Infective Drugs Advisory Committee. General Function of the Committee: To provide advice and recommendations to the Agency on FDA’s regulatory issues. Date and Time: The meeting will be held on September 5, 2012, from 8 a.m. to 5 p.m. Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (rm. 1503), Silver Spring, MD 20993– 0002. Information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: https://www.fda.gov/ AdvisoryCommittees/default.htm; under the heading ‘‘Resources for You,’’ click on ‘‘Public Meetings at the FDA White Oak Campus.’’ Please note that visitors to the White Oak Campus must enter through Building 1. Contact Person: Diane Goyette, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993–0002, 301– 796–9001, FAX: 301–847–8533, email: AIDAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1–800– 741–8138 (301–443–0572 in the Washington, DC area) to find out further information regarding FDA advisory committee information. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s Web site at https://www.fda. gov/AdvisoryCommittees/default.htm and scroll down to the appropriate advisory committee meeting link, or call the appropriate advisory committee information line to learn about possible modifications before coming to the meeting. Agenda: The committee will discuss new drug application (NDA) 201688, E:\FR\FM\10JYN1.SGM 10JYN1

Agencies

[Federal Register Volume 77, Number 132 (Tuesday, July 10, 2012)]
[Notices]
[Page 40622]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-16776]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Mine Safety and Health Research Advisory Committee, National 
Institute for Occupational Safety and Health (MSHRAC, NIOSH)

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following meeting for the aforementioned 
committee:

    Times and Dates:

8:30 a.m.-5:15 p.m., August 20, 2012
8:30 a.m.-4:30 p.m., August 21, 2012

    Place: Hilton Garden Inn Pittsburgh/Southpointe, 1000 Corporate 
Drive, Canonsburg, Pennsylvania 15317. Telephone: (724) 743-5000, 
Fax: (724) 743-5010.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 50 people.
    Purpose: This committee is charged with providing advice to the 
Secretary, Department of Health and Human Services; the Director, 
CDC; and the Director, NIOSH, on priorities in mine safety and 
health research, including grants and contracts for such research, 
30 U.S.C. 812(b)(2), Section 102(b)(2).
    Matters To Be Discussed: The meeting will focus on engineering 
noise controls, reducing coal dust exposures, reducing injuries 
through improved illumination, demographics survey of the mining 
industry, implementation of the National Academy of Science's 
recommendations, oxygen supply partnership, safety culture, 
occupational health and safety management systems, preventing coal 
dust explosions, and reducing silica exposures.
    Agenda items are subject to change as priorities dictate.
    Contact Person for More Information: Jeffery L. Kohler, Ph.D., 
Designated Federal Officer, MSHRAC, NIOSH, CDC, 626 Cochrans Mill 
Road, Mailstop P05, Pittsburgh, Pennsylvania 15236, telephone (412) 
386-5301, fax (412) 386-5300.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining 
to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention 
and the Agency for Toxic Substances and Disease Registry.

    Dated: July 2, 2012.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2012-16776 Filed 7-9-12; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.